Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Evoke Wealth LLC

Evoke Wealth LLC increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,071 shares of the pharmaceutical company’s stock after purchasing an additional 83 shares during the period. Evoke Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $431,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Horizon Investments LLC lifted its position in shares of Vertex Pharmaceuticals by 1.8% in the fourth quarter. Horizon Investments LLC now owns 4,969 shares of the pharmaceutical company’s stock valued at $2,001,000 after acquiring an additional 86 shares in the last quarter. Advisors Asset Management Inc. raised its stake in Vertex Pharmaceuticals by 4.3% in the 4th quarter. Advisors Asset Management Inc. now owns 27,612 shares of the pharmaceutical company’s stock valued at $11,119,000 after purchasing an additional 1,145 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Vertex Pharmaceuticals by 1.3% in the 4th quarter. William Blair Investment Management LLC now owns 77,532 shares of the pharmaceutical company’s stock valued at $31,222,000 after purchasing an additional 983 shares in the last quarter. Parallel Advisors LLC boosted its stake in Vertex Pharmaceuticals by 2.0% during the 4th quarter. Parallel Advisors LLC now owns 7,335 shares of the pharmaceutical company’s stock worth $2,954,000 after purchasing an additional 143 shares during the last quarter. Finally, Cibc World Markets Corp grew its stake in Vertex Pharmaceuticals by 13.9% during the 4th quarter. Cibc World Markets Corp now owns 46,339 shares of the pharmaceutical company’s stock valued at $18,661,000 after acquiring an additional 5,665 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. StockNews.com raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 11th. Scotiabank boosted their target price on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a “sector perform” rating in a report on Tuesday, February 11th. Piper Sandler cut their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.1 %

VRTX stock opened at $512.52 on Thursday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company’s 50 day moving average price is $464.06 and its 200 day moving average price is $462.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a market capitalization of $131.61 billion, a price-to-earnings ratio of -232.96, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.